Skip to main content
. 2017 Jul 5;8(11):1988–1994. doi: 10.7150/jca.18900

Table 3.

Response rates by modified RECIST

Sorafenib+vitamin K (n=29) Sorafenib alone (n=36)
Complete response n (%) 0 (0) 0 (0)
Partial response n (%) 10 (34) 5 (14)
Stable disease n (%) 10 (34) 5 (14)
Progressive disease n (%) 9 (31) 25 (69)
Not assessable n (%) 0 (0) 1 (3)
aDisease control rate n (%) 20 (69.0) 8 (22.9)

a P<0.001

RECIST: Response Evaluation Criteria in Solid Tumors